title: Long-term experience with continuous duodenal levodopa-carbidopa infusion (Duodopa): report of six patients.
authors.forename: F
authors.initials: F
authors.lastname: Raudino
authors.forename: P
authors.initials: P
authors.lastname: Garavaglia
authors.forename: C
authors.initials: C
authors.lastname: Pianezzola
authors.forename: G
authors.initials: G
authors.lastname: Riboldazzi
authors.forename: S
authors.initials: S
authors.lastname: Leva
authors.forename: M
authors.initials: M
authors.lastname: Guidotti
authors.forename: G
authors.initials: G
authors.lastname: Bono
mesh_terms: D000368:Aged; D000978:Antiparkinson Agents / Q000008:administration & dosage*; D002230:Carbidopa / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004386:Duodenum / Q000187:drug effects / Q000378:metabolism; D004409:Dyskinesia, Drug-Induced / Q000517:prevention & control; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007260:Infusion Pumps / Q000706:statistics & numerical data*; D007980:Levodopa / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D013995:Time; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000978:Antiparkinson Agents; D007980:Levodopa; D002230:Carbidopa